Due to the high affinity of the targeting moieties to the TfR in the BBB cells, ligand-modified NPs are likely to be entrapped within these cells, consequently reducing the number of NPs’ that effectively cross the barrier and reach the GBM cells. The gene discussed is TFRC; the disease is glioblastoma.